CCL2 is also a chemoattractant for MDSCs, which triggers MDSC-dependent suppression of immunological control over the tumor [190,237], stimulates macrophage-mediated angiogenic switch [238,239] and the promotion of tumor growth by these cells [237,240]. This evidence concerns the gene CCL2 and neoplasm.